肿瘤细胞治疗研究
英文原题：Dendritic cell vaccine trials in gliomas: Untangling the lines.
胶质母细胞瘤是一种致命的脑肿瘤，迄今为止尚无任何显著成功的治疗方法。
胶质母细胞瘤是一种致命的脑肿瘤，迄今为止尚无任何显著成功的治疗方法。包括肽疫苗和树突状细胞（DC）疫苗在内的肿瘤抗原靶向免疫治疗平台，已延长了血液系统恶性肿瘤患者的生存期。胶质母细胞瘤相对“冷”的肿瘤免疫微环境及其异质性，已被证明是DC疫苗转化应用和疗效的主要限制因素。此外，胶质母细胞瘤中的许多DC疫苗试验由于缺乏同期对照、没有任何对照比较或患者人群不一致而难以解读。在此，我们综述与DC疫苗相关的胶质母细胞瘤免疫生物学方面，回顾针对胶质母细胞瘤的DC疫苗的临床经验，讨论临床试验设计中的挑战，并总结结论以及为患者开发有效DC疫苗的未来研究方向。
Glioblastoma is a deadly brain tumor without any significantly successful treatments to date. Tumor antigen-targeted immunotherapy platforms including peptide and dendritic cell (DC) vaccines, have extended survival in hematologic malignancies. The relatively "cold" tumor immune microenvironment and heterogenous nature of glioblastoma have proven to be major limitations to translational application and efficacy of DC vaccines. Furthermore, many DC vaccine trials in glioblastoma are difficult to interpret due to a lack of contemporaneous controls, absence of any control comparison, or inconsistent patient populations. Here we review glioblastoma immunobiology aspects that are relevant to DC vaccines, review the clinical experience with DC vaccines targeting glioblastoma, discuss challenges in clinical trial design, and summarize conclusions and directions for future research for the development of effective DC vaccines for patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
